冠心病靶向抗炎疗法的研究新进展  

New progress in the research of targeted anti-inflammatory therapy for coronary heart disease

作　　者：罗鹏[1] 吴延庆[1] LUO Peng;WU Yanqing(Department of Cardiology,the Second Affiliated Hospital of Nanchang University,Nanchang,Jiangxi 330006,China)

机构地区：[1]南昌大学第二附属医院心血管内科

出　　处：《中国动脉硬化杂志》2018年第11期1170-1176,共7页Chinese Journal of Arteriosclerosis

基　　金：国家自然科学基金项目(8166020210)

摘　　要：冠心病是威胁我国城乡居民健康的首要疾病之一。近来研究显示,慢性炎症是动脉粥样硬化诱导和发展的核心致病机制,炎症反应的各个通路成为冠心病治疗的靶点。但目前冠心病二级预防尚未推荐靶向抗炎药物。2017年欧洲心脏病学会年会(ESC 2017)公布的CANTOS研究证实,康纳单抗通过抗炎显著降低目标人群心血管病风险。这一里程碑意义的研究揭示了在传统的降脂、抗栓治疗时代后,抗炎疗法这一冠心病治疗的新篇章。近年来,各类冠心病靶向抗炎药物的研究进展迅速,现就冠心病的靶向抗炎疗法的研究进展作一综述。Coronary heart disease is one of the leading diseases that threaten the health of urban and rural residents in China.Recent studies have shown that chronic inflammation is the core pathogenic mechanism of the induction and development of atherosclerosis, and various pathways of inflammatory response have become targets for the treatment of coronary heart disease.However, no specific target anti-inflammatory drugs have been recommended for secondary prevention of coronary heart disease.The CANOTOS study, published at the European Society of Cardiology Congress 2017 (ESC 2017), confirmed that canakinumab significantly reduces cardiovascular risk in the target population through anti-inflammatory action.This landmark study reveals that anti-inflammatory therapy is a new chapter in the treatment of coronary heart disease after the age of traditional lipid-lowering and antithrombotic therapy.In recent years, rapid progress has been made in the research of targeted anti-inflammatory drugs for various types of coronary heart disease.The current progress in the research of targeted anti-inflammatory therapy for coronary heart disease is reviewed.

关 键 词：冠心病 抗炎疗法 康纳单抗 托珠单抗 

分 类 号：R5[医药卫生—内科学]